

# Minutes of the HPRA Leadership Team Licensing and regulation section

- Friday 25 July 2025 at 9.30am
- Hybrid Teams call and CEO's meeting room 3<sup>rd</sup> floor

Chair	Present	Apologies
Ms R. Purcell, Deputy	Mr S. d'Art, Director of ICT and	Ms E. Stuart, Director of
Chief Executive	Business Services	Human Resources and
		Development
	Dr F. Lonsdale, Director of Human	Ms G. Power, Director of
	Medicines	Compliance
	Dr J.G Beechinor, Director of	Dr L. Nolan, Chief Executive
	Veterinary Science	
	Ms S. Curran, Director of Human	
	Products Monitoring	
	r roducts Worldoning	
	Dr N. MacAleenan, Director of	
	Medical Devices	

Minutes taken by Ms A. Holly, Corporate Affairs Manager

Please note that certain information, such as personal data, confidential/commercially sensitive information, and pending prosecutions may have been removed from these minutes.

# 1 ADOPTION OF THE AGENDA

The meeting adopted the agenda.

# 2 DECLARATIONS OF INTEREST

There was nothing to report.

# 3 ADOPTION OF THE MINUTES OF THE LAST MEETING

The minutes of the meeting of 18 July 2025 were adopted and signed.

MGT-F0035-3 1/2

<sup>\*</sup>Approved via written procedure

<sup>\*\*</sup>Attended part of the meeting

# 4 MATTERS ARISING

There was nothing to report.

# **5 PUBLIC HEALTH ISSUES**

#### 5.1 NSAI

An update was provided on the recent EU joint assessment for re-designation of NSAI under the MDR.

# 5.2 Pharmacovigilance non-compliance

A further update was provided on the approach to be taken following a recent inspection of a Marketing Authorisation Holder (MAH).

#### **6 PRODUCT ISSUES**

# 6.1 Committee for Medicinal Products for Human Use (CHMP)

An update was provided on the outcome of the CHMP vote on Kisunla.

# 7 REJECTIONS, SUSPENSIONS AND REVOCATIONS

There was nothing to report.

# 8 LICENSING TABLES

The relevant tables submitted were approved.

# 9 AOB

#### **9.1 NVPS**

An update was provided confirming that the implementation of S.I. No. 51 of 2025 has been deferred until 1 December 2025 to allow additional time for full adoption of the NVPS.

MGT-F0035-3 2/2